The vitamin E derivative (þ)a-tocopheryl succinate (a-TOS) exerts pro-apoptotic effects in a wide range of tumors and is well tolerated by normal tissues. Previous studies point to a mitochondrial involvement in the action mechanism; however, the early steps have not been fully elucidated. In a model of acute promyelocytic leukemia (APL) derived from hCG-PML-RARa transgenic mice, we demonstrated that a-TOS is as effective as arsenic trioxide or all-trans retinoic acid, the current gold standards of therapy. We also demonstrated that a-TOS induces an early dissipation of the mitochondrial membrane potential in APL cells and studies with isolated mitochondria revealed that this action may result from the inhibition of mitochondrial respiratory chain complex I. Moreover, a-TOS promoted accumulation of reactive oxygen species hours before mitochondrial cytochrome c release and caspases activation. Therefore, an in vivo antileukemic action and a novel mitochondrial target were revealed for a-TOS, as well as mitochondrial respiratory complex I was highlighted as potential target for anticancer therapy.
Introduction
The introduction of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) in the therapy of acute promyelocytic leukemia (APL) has transformed this highly fatal disease to one that is highly curable. 1 However, some patients develop a differentiation syndrome, a life-threatening complication, most commonly after ATRA administration. The concomitant use of anthracycline in induction chemotherapy potentially decreases the incidence of this complication but its use may be restricted, particularly in patients with heart failure. 2 In this sense, treating elderly patients for APL remains a clinical challenge. 3, 4 Therefore, effective and less toxic therapeutic strategies for APL are needed.
Recently, we demonstrated the pro-apoptotic action of the vitamin E derivative (þ)a-tocopheryl succinate (a-TOS) in APL cell lines NB4 (ATRA sensitive), in NB4-R2 (ATRA resistant) and in leukemic cells derived from patients; a-TOS did not affect proliferation or differentiation of normal hematopoietic progenitors. 5 In fact, a-TOS is well tolerated in doses that induce growth inhibition and apoptosis in several tumor types in animal models. 6, 7 Both a-TOS and ATO have been described as anticancer drugs that target mitochondria (known as mitocans), which are thought to exert their cytotoxic effects primarily by interfering with the generation of reactive oxygen species (ROS). 8 Indeed, the exquisite sensitivity of APL to ATO treatment has been recently demonstrated to be mediated by PML-RARa oxidation and subsequent degradation in an ROS-dependent process. 9 Interestingly, Weber et al. 10 demonstrated that p0 cells that lack mitochondrial respiratory chain (MRC) activity are insensitive to a-TOS toxicity. However, few data are available regarding the early molecular events underlying this action.
The MRC complexes (I-IV) in the inner membrane of mitochondria transport electrons from NADH or FADH 2 to oxygen. The reaction involving complexes I, III and IV is coupled to the pump of protons (H þ ) from the matrix into the mitochondrial intermembrane space. Storage of energy as proton-motive force, the main component of which is the mitochondrial membrane potential (Dc), drives H þ back into the mitochondrial matrix and provides energy for ATP synthesis by F o F 1 -ATP synthase (complex V). 11 Yamamotto et al. 12 reported that a-TOS dissipates Dc in isolated mitochondria and Dong et al. 13 that a-TOS specifically inhibits MRC complex II, resulting in ROS accumulation. In the present work, we bring new insights to this mechanism. We assessed the in vivo effects of a-TOS in an APL murine transplantation model and addressed mechanistic aspects in APL cells and mitochondria isolated from rat livers. We demonstrated that treatment with a-TOS alone significantly reduces leukemic burden and increases survival to the same extent as ATRA or ATO. In addition, we identified MRC complex I as a novel a-TOS target.
Materials and methods

Assessment of in vitro apoptotic effect of a-TOS
Apoptosis was evaluated by three different methods: annexin V and propidium iodide assay, DNA fragmentation analysis and microscopic analysis of morphologic changes. NB4 cells were treated with 75 mM a-TOS or the vehicle control (DMSO, 0.1% v/v) for 6, 12 and 24 h. ATO (Sigma, St Louis, MO, USA) was used as a positive control (2 mM for 24 h).
Mitochondrial membrane potential (Dc) in NB4 cells
NB4 cells were incubated with 75 mM a-TOS or the DMSO vehicle control for the periods indicated, followed by incubation with JC-1 stain (1 mM) (Molecular Probes, Eugene, OR, USA) at 37 1C in a 5% CO 2 atmosphere for 20 min. Cells were then washed, and the pellet was suspended in phosphate-buffered saline and acquired in a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA).
Isolation of rat liver mitochondria and mitochondrial respiration (oxygen consumption)
Mitochondria were isolated by standard differential centrifugation as previously described.
14 Mitochondrial respiration was monitored polarographically by an oxygraph equipped with a Clark-type oxygen electrode (Gilson Medical Electronics, Middleton, WI, USA).
Preparation of submitochondrial particles and complex I (NADH quinone oxidoreductase) and complex II (succinate quinone oxidoreductase) activity
The mitochondrial pellet was frozen and stored at À20 1C. After 24 h, the pellet was thawed and resuspended with the homogenization medium to 20 mg protein/ml. The mitochondrial suspension was subjected five times to 10 s of sonic oscillation (80 W) at 30-s intervals. The suspension was centrifuged at 9750 g for 10 min, and the submitochondrial particles in the supernatant were isolated by centrifugation at 100 000 g for 1 h and stored at À80 1C.
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Kinetic assays were carried out in a Shimadzu PC-45000 spectrophotometer (Shimadzu Corp., Kyoto, Japan) equipped with a magnetic stirrer for continuous agitation at 30 1C according to the method of Trounce et al. 16 with minor modifications. NADH quinone oxidoreductase activity measures NADH oxidation when coupled to the complex I reduction of decylubiquinone (DB) by monitoring the decrease of NADH absorbance at 340 nm (e ¼ 5.3/M/cm) (Supplementary Figure 1) . The reaction media were composed of 125 mM sucrose, 65 mM KCl, 10 mM HEPES-KOH, 100 mM NADH and 2 mM KCN (pH 7.4). Succinate quinone oxidoreductase activity measures the reduction of 2,6-dichlorophenolindophenol when coupled to complex II reduction of DB by monitoring absorbance at 600 nm (e ¼ 12.14 M/cm) (Supplementary Figure 2) . The reaction media were composed of 125 mM sucrose, 65 mM KCl, 10 mM HEPES-KOH, 20 mM succinate, 2 mM rotenone, 2 mg/ml antimycin A and 5 mM 2,6-dichlorophenolindophenol (pH 7.4). For both assays, different amounts of DB (Sigma, USA) diluted in ethanol (0.1% v/v) were added, and the reactions were initiated by the addition of submitochondrial particle (30 mg/ml). For the kinetic inhibition experiments, a-TOS was added at various concentrations with DMSO maintained at a final concentration of 0.1% (v/v). Rotenone (2 mM) and thenoyltrifluoroacetone (10 mM) were added as positive controls for inhibition of complex I and complex II, respectively, and resulted in 499% (rotenone) and 95% (thenoyltrifluoroacetone) inhibition in all preparations.
Western blot analysis
Cell fractionation for cytochrome c experiments was performed by mechanical fractionation as previously described. 17 Whole-cell extracts were prepared by washing the cells twice with phosphate-buffered saline followed by lysis in RIPA buffer (150 mM NaCl, 1.5 mM MgCl 2 , 10 mM NaF, 10% glycerol, 4 mM EDTA, 1% Triton X-100, 0.1% SDS, 1% sodium deoxycholate, 50 mM HEPES (pH 7.4)) plus protease-inhibitor mixture (1 mM PMSF, 10 mg/ml leupeptin and 10 mg/ml aprotinin) and sodium orthovanadate (10 mM) for 15 min on ice, followed by centrifugation at 10 000 g for 10 min at 4 1C. Protein concentration was determined by the Bradford assay. Cell lysates were analyzed by 12% SDS-PAGE. After protein transfer, polyvinylidene difluoride membranes (Sigma, USA) were incubated with specific primary antibodies and secondary horseradish peroxidaseconjugated antibodies, and antibody binding was visualized in high sensitivity films with ECL Western Blot detection reagents (Amersham Biosciences, Piscataway, NJ, USA). We used rabbit polyclonal antibodies against caspase-3, cleaved caspase-3, caspase-9 and RARa (RP115); rabbit monoclonal antibodies against AKT (C67E7), Ser473 P-AKT (193H12), IKBa (44D4); and mouse monoclonal antibody against b-actin (8H10D10) (Cell Signaling, Boston, MA, USA), and mouse monoclonal antibodies against cytochrome c (clone 7H82C12; BD Pharmingen, San Diego, CA, USA).
Murine syngeneic transplant
hCG-PML-RARa transgenic mice (TM), previously described, 18 were maintained in a specific pathogen-free environment and observed for signs of disease. Because of the low penetrance and long latency of the murine APL model, we used a syngeneic transplantation model. Leukemic TM were killed, and cells were obtained by mechanical disruption of the spleen. Wild-type littermates were used as transplant recipients after sublethal irradiation (700 cGy, 33 cGy/min). Twelve hours after irradiation, APL cells were thawed and 3 Â 10 6 viable cells were injected intravenously. Animals were kept in specific pathogenfree conditions. In pilot experiments, all untreated animals died of acute leukemia between 3 and 4 weeks.
Treatment of transplanted mice
On day 5 after transplantation, mice were randomly assigned to one of six treatment groups: ATRA 1.5 mg/g/day (n ¼ 14); ATO 2.5 mg/g/day (n ¼ 15); a-TOS 50 mg/g/day (n ¼ 15); a-TOS þ ATO (n ¼ 15); a-TOS þ ATRA (n ¼ 14); or DMSO vehicle control. Drugs were administered via intraperitoneal injection for 21 consecutive days. Doses of ATRA and ATO were selected based on a previous study and were shown to induce leukemia remission with low toxicity. 19 Dose of a-TOS was based in a previous study 20 and adjusted after our pilot studies. Hematological counts were monitored biweekly, and mice were killed when moribund or at day 180 after transplantation. The study was approved by the local ethical committee for animal experimentation (protocol 037/2003).
Assessment of in vivo apoptotic effect of a-TOS
Fifteen C57BL/6 mice were treated with a-TOS (n ¼ 6) or DMSO (n ¼ 9) for 6 days after transplantation, as described above. Mice were killed 6 h after the last dose of a-TOS or DMSO. Cells from the liver and spleen were obtained by mechanical dissociation, as previously described. The percentage of apoptotic cells was assessed by flow cytometry in a population positive for CD117 (myeloid marker expressed by leukemic cells of murine transgenic model) with the annexin V assay, as described above.
Statistics
Survival of the transplanted mice was analyzed by KaplanMeier curves. All mice alive at 180 days post-transplantation were censored at this time. Survival curves were compared by log-rank test. All other data were expressed as median ± 25-75 percentiles, and statistical inference assessed by the nonparametric Mann-Whitney (to compare two groups) and the Kruskal-Wallis followed by Dunnett's post-test (to compare more than two groups). Type 1 error (a) 45% was considered not acceptable. All statistical analyses were performed with SPSS 13.0 statistical software (SPSS Inc., Chicago, IL, USA).
Results
a-TOS-induced cell death in APL is characteristic of apoptosis
We previously reported that 24 h a-TOS treatment induces NB4 cell death with an estimated effective dose 50% (ED50) of 75 mM. 5 In order to better characterize the time course of the events related to the a-TOS toxicity, we assessed the treatment effects (ED50) at various time points. NB4 cell death induced by 75 mM a-TOS began B12 h after treatment and was characteristic of apoptosis, as demonstrated by externalization of phosphatidylserine (mean and 95% confidence interval (95% CI)) by 40.2% (37.5-42 Figure 1e ). We also confirmed that the a-TOS effects are not restricted to APL, as previously reported, 6, 7 by assessing its ED50 in other leukemic cell lines using a XTT-based screening assay (Supplementary Table 1 ). In sequence, we decided to further investigate the mechanisms of a-TOS-induced cytotoxicity in APL since it is a disease with well-defined molecular events.
a-TOS induced an immediate dissipation of mitochondrial membrane potential (Dc) in APL cells
Dissipation of Dc is an early marker of irreversible cell damage, 21 so we began by monitoring the effect of a-TOS on this parameter in NB4 cells. Unexpectedly, a consistent decrease of Dc relative to the control was revealed, regardless of length of incubation with the drug (Figure 2a ) and timely a-TOS inhibits MRC complex I in APL GAS dos Santos et al dissociated of all other apoptosis markers ( Figure 1 ). Since for all incubation times presented in Figure 2a , we need to assume an at least 20 min delay due to the washing step, we adjusted the method by excluding it in order to measure the real-time internalization of JC-1, a fluorescent probe that depends on Dc to accumulate into mitochondria. In the control, the JC-1 polymer fluorescence increased in a time-dependent manner ( Figure 2b ) whereas fluorescence decreased in a-TOS-treated cells (Figure 2c ). The following possibilities could account for this immediate and direct effect on mitochondria: uncoupling, inhibition of the MRC or induction of mitochondrial permeability transition (MPT). MPT is a Ca 2 þ -dependent permeabilization of the inner mitochondrial membrane, which is caused by diverse stimuli including oxidative stress and is believed to be involved in cell death. In MPT, the inner and outer mitochondrial membranes communicate via high-conductance channels that dissipate Dc and release cytochrome c. 22 However, MPT was not the cause because NB4 cells under the same condition did not release cytochrome c before 12 h treatment (Figure 2c , insert) and isolated rat liver mitochondria did not swell in response to a-TOS (data not shown). Next, we evaluate if this immediate effect on Dc could be explained by the a-TOS action on AKT and NFkB signaling, as these pathways had been described as targets. a-TOS behaved like an MRC inhibitor, not an uncoupler or MPT inducer, in isolated rat liver mitochondria and permeabilized APL cells
To identify the action mechanism of a-TOS in mitochondria, we performed assays with isolated rat liver mitochondria, a classic model for mitochondrial studies. a-TOS (10-250 mM) did not increase the rate of state 4 respiration (Table 1) , which is a direct evidence of mitochondrial uncoupling. Indeed, in the same assays, the ionophore carbonyl cyanide m-chlorophenylhydrazone, used as a positive control for uncoupling, markedly increased the respiration rate. Then, we tested whether a-TOS could inhibit state 3 respiration, a feature of MRC inhibitors. a-TOS concentration dependently inhibited state 3 respiration in mitochondria energized with glutamate/malate, but not in organelles energized with succinate (Table 1) . Glutamate and malate are oxidized in the mitochondrial matrix to generate NADH and support respiration mainly through MRC complex I; succinate, in turn, generates FADH 2 directly in the MRC complex II. Therefore, these results suggest that a-TOS inhibits MRC complex I.
To confirm these results in APL cells, we tested if a-TOS could inhibit the respiration of NB4 cells when supported exclusively by glutamate/malate as a model of complex I-driven respiration or by succinate (plus rotenone) as a model of complex II-driven respiration. Figure 3a shows a concentration-dependent inhibition of a-TOS for complex I-driven respiration, but not for complex II (Figure 3b ). The inhibition of the respiration rate (mean and 95% CI) was of 17.8% (13. a-TOS acted as a moderate uncompetitive inhibitor of MRC complex I and a weak inhibitor of complex II
The kinetic parameters for NADH quinone oxidoreductase (complex I) and succinate quinone oxidoreductase (complex II) were determined in rat liver submitochondrial particles. V max values were estimated in 0.68 mmol/mg/min for complex I a-TOS inhibits MRC complex I in APL GAS dos Santos et al ( Figure 3e) ; an uncompetitive inhibition pattern is evident from the double-reciprocal plot (Figure 3f ). These results demonstrate that a-TOS acts as a moderate uncompetitive inhibitor of MRC complex I and a weak inhibitor of complex II.
a-TOS induced early ROS accumulation in APL cells, which preceded cytochrome c release and caspases activation
Because MRC inhibition may increase mitochondrial ROS generation, 24 we asked whether a-TOS produces this effect. ROS accumulation in NB4 cells was revealed as early as 3 h after incubation with 75 mM a-TOS (Figure 4a) . Next, to confirm whether a-TOS generates ROS directly in mitochondria we used a mitochondrial-specific probe (MitoSox, Molecular Probes, USA) derived from dihydroethidium and with an attached triphenylphosophonium cation moiety that accumulates specifically in the organelles. 25 Figure 4b shows that the treatment with a-TOS induces ROS generation in mitochondria of NB4 cells. We observed a similar effect with rotenone (an inhibitor of MRC complex I), antimycin A (an inhibitor of complex III) and to a lesser extent with thenoyltrifluoroacetone (an inhibitor of complex II) (Figures 4a and b) . In addition, a progressive loss of reduced glutathione in cells treated with a-TOS was revealed (Figure 4c ). It is important to point out that mitochondrial cytochrome c release (Figure 2c , insert) and cleavage of caspases 3 ( Figure 1d ) and 9 (Figure 1e ), typical markers of apoptosis, were observed only after 12 h of treatment with a-TOS under the same conditions. To better evaluate the role of ROS in a-TOS-induced cell death, we tested typical ROS scavengers: superoxide dismutase þ catalase, trolox and MitoQ (Supplementary Figure 3) . However, they were ineffective to prevent a-TOS-induced ROS accumulation. N-acetylcysteine (NAC, 5 mM) attenuated ROS accumulation only in the first 3 h of treatment (Figure 4d ). Moreover, NAC did not prevent a-TOS-induced cell toxicity (Figure 4e ). 
a-TOS inhibits MRC complex I in APL GAS dos Santos et al
Myeloid progenitors from PML-RARa TM are more susceptible to ROS accumulation than their wide types counterparts
In order to assess whether the oncoprotein PML-RARa could induce a state of sensitivity toward ROS accumulation, we compared levels of mitochondrial ROS in myeloid progenitors from TM and wild-type littermate controls (12 weeks old). Cells from TM accumulated more ROS in a basal state and after stimuli with either a-TOS (75 mM) or the pro-oxidant t-butyl hydroperoxide (100 mM) than wild-type controls (Figure 5a ).
a-TOS promoted partial degradation of PML-RARa oncoprotein in NB4 cells
Next, we tested whether a-TOS could promote degradation of the oncoprotein PML-RARa. a-TOS (75 mM) induced a partial degradation of PML-RARa after 48 h treatment. At the same time, as expected, ATO (2 mM) induced total degradation of the oncoprotein. This implies that although degradation of PMLRARa happens, it is not the major mechanism of a-TOS-induced toxicity in APL. This result corroborates the evidence that a-TOS is not exquisitely more effective in the APL cell line when compared with other leukemia cell lines (as presented in Supplementary Table 1) .
a-TOS prolonged survival in the murine syngeneic transplant model
Because of the low penetrance and long latency of the murine APL model, we used a syngeneic transplantation model to demonstrate the antileukemic action of a-TOS in vivo. Figure 6a shows survival curves of syngeneic mice transplanted with APL cells from hCG-PML-RARa TM. Median survival in the control group was 25.6 days (95% CI ¼ 20.9-30.3 days); all control mice died of leukemia, as determined by analysis of peripheral blood, bone marrow and spleen (Table 2 ). In contrast, median survival in the treated groups was 142.7 days (95% CI ¼ 111.8-173.7 days) for the ATRA-treated mice, 162.1 days (95% CI ¼ 137.9-186.3 days) for the ATO-treated mice, 160.4 days (95% CI ¼ 134.2-186.6 days) for the a-TOS-treated mice, 124.5 days (95% CI ¼ 83.9-165.1 days) for the a-TOS þ ATRA-treated mice and 163.0 days (95% CI ¼ 139.9-186.1 days) for the a-TOS þ ATO-treated mice. Survival in the treated groups was significantly longer than in the control group, although no significant difference was observed among the different treated groups. As previously described, 19 ATO or ATRA treatment induces high rates of remission and prolonged survival. Furthermore, compared with control, a-TOS alone or combined with ATRA or ATO significantly reduced leukemic infiltration of the bone marrow and spleen ( Figure 6b ; Table 2 ). Therefore, a-TOS cleared leukemic cells in the murine model as effectively as did ATRA or ATO. Figure 6c shows the percentage of apoptotic cells in the spleen of recipient mice of the syngeneic transplant model. The analysis was restricted to the myeloid marker CD117 þ cells, which is expressed by APL cells of the TM model. 26 Treatment with a-TOS significantly increased the mean number of apoptotic cells compared with control (65.1 vs 37.2%, P ¼ 0.007). Morphologic analysis confirmed this result (Figure 6d ) and similar results were obtained for leukemic cells infiltrating the liver (data not shown). 
a-TOS induces apoptosis in APL cells in vivo
Table 2
Hematologic end points for the different treatment groups evaluated in the APL murine syngeneic model
Discussion
This study reveals an immediate mitochondrial membrane potential dissipation promoted by a-TOS in NB4 cells, in agreement with a previous report on isolated mitochondria. 12 However, a-TOS promoted cytochrome c release only after 12 h of treatment and mitochondria isolated from rat liver did not swell when exposed to the drug, demonstrating that MPT is not involved. In addition, a-TOS did not increase state 4 respiration rate in isolate rat liver mitochondria, ruling out involvement of uncoupling action and suggesting that MRC is the most likely a-TOS target. Indeed, we found that a-TOS inhibits both MRC complex I and II activities. However, the K I value for complex I inhibition by a-TOS was several-fold lower than for complex II, suggesting that MRC complex I is the primary drug target. We stress that our kinetic assays for both complexes I and II measured an activity which was strictly dependent on DB concentration. This strategy, which focuses on the hydrophobic domains of the complexes, is reliable for mechanistic studies of hydrophobic compounds that presumably interact with the quinone-binding sites. For example, adaphostin has been characterized as an inhibitor of MRC complex III through an assay which uses decylubiquinol (reduced form of DB) as the electron donor. 27 This may be the reason by which our results disagree with a previous study reporting lack of complex I inhibition by a-TOS. 13 In that case, the assay was performed with a hydrophilic electron carrier, phenazine monosulfate, which is not suitable for evaluating the specific effect of an inhibitor on quinone-binding sites because the activity measured does not depend on quinone concentration; in fact, the assay is suitable to determine succinate dehydrogenase activity in preparations devoid of complex II hydrophobic domains. 28 Moreover, our results of oxygen consumption in digitoninpermeabilized NB4 cells indicate that the action of a-TOS in APL seems to be similar to our findings in rat liver mitochondria.
Because a-TOS appears to accumulate in mitochondria with several-fold higher concentrations than in other cell compartments, 29 we cannot exclude the possibility that both complexes I and II were inhibited by a-TOS in vivo. In fact, tumors derived from complex II-mutated cells were more resistant to a-TOS in vivo and complex I-defective cells displayed normal sensitivity to a-TOS in vitro, suggesting that a-TOS specifically targets complex II. 30 However, reverse electron transfer from succinate and complex II to complex I generates ROS. 24, 31 In a model of reverse electron transfer induced by a-TOS, the primary site of ROS production would be complex I, so the action of the drug would be impaired by a complex II target deletion. Moreover, ROS production in complex I is usually enhanced by a high NADH/NAD þ ratio, which occurs when complex I is inhibited. 31 Complex I is a target for apoptosis induced by different stimuli; its involvement in both caspase-dependent and caspaseindependent processes has been demonstrated. In apoptosis induced by cytotoxic T lymphocytes or natural killer cells, a-TOS inhibits MRC complex I in APL GAS dos Santos et al granzyme A cleaves an iron-sulfur subunit of complex I (NDUFS3) altering its enzymatic activity and generating ROS. 32 Similarly, in a decisive event of caspase-dependent apoptosis, caspase-3 cleaves the NDUFS1 subunit generating ROS. 33 Moreover, inactivation of apoptosis induction factor, a chaperone for complex I, results in deficiency in several subunits of this complex from carcinoma cell lines, increasing susceptibility to apoptosis and abrogating tumorigenicity in vivo. 34 cAMP-dependent protein kinase A phosphorylates the complex I NDUFS4 subunit inducing its function and reducing ROS accumulation; moreover, complex I was described as a 'regulable' and vulnerable pacemaker of mitochondrial respiratory function. 35 Recently, the Warburg effect or aerobic glycolysis 36 is regaining attention as a characteristic metabolic phenotype of cancer which could be used as a therapeutic target. 37, 38 Indeed, a 'complex I-centered' mechanism of ROS production has been described for dichloroacetate, a welldocumented inhibitor of pyruvate dehydrogenase kinase; the drug reverses the glycolytic phenotype and induces apoptosis in cancer cells. 39 This scenario raises the possibility that cancer cells may be more sensitive than normal cells to molecules targeting complex I function, as a-TOS does. On the other hand, pharmacological inhibition of complex I has sometimes been associated with neurologic dysfunction, 40 thus requiring care in the potential use of a-TOS treatment in the clinical setting.
We observed that ROS accumulation precedes a-TOSinduced cytochrome c release and caspase activation. This finding is consistent with previous reports demonstrating that ROS accumulation is a pathway for a-TOS-induced apoptosis in other cancer cell types. 41, 42 Furthermore, myeloid precursors from PML-RARa TM accumulate more ROS at basal state and after stimuli than cells from control mice. This is consistent with previous reports linking ATO-induced degradation of the PMLRARa oncoprotein and a direct binding of ATO to ROS-sensitive cysteine residues in the oncoprotein.
9,43 a-TOS induced only a partial degradation of PML-RARa in NB4 cells, as expected for an agent that is not APL specific as illustrated by the results of screening assays conducted with other leukemia cell lines (Supplementary Table 1 ). The low efficacy of the ROS scavenger NAC in reducing a-TOS-induced toxicity in NB4 cells and the fact that a-TOS-induced ROS accumulation was not reversed by several antioxidants suggest that ROS accumulation and energetic failure resulting from MRC inhibition, mainly complex I, is the cause of a-TOS-induced toxicity in APL cells. Alternatively, since a specific antioxidant action in the mitochondrial compartment would be required in order to prevent the cell toxicity induced by a-TOS, it is conceivable that this lack of action of antioxidants is related to subcellular distribution. Our results cannot definitively exclude a concomitant generation of ROS by effect of a-TOS in cellular compartments other than MRC. However, Weber et al. 10 have demonstrated that p0 cells, which are devoid of MRC function, are insensitive to a-TOS, implying that the effect in MRC is essential to apoptosis.
We previously demonstrated that a-TOS exerts antileukemic activity in vitro against ATRA-sensitive and ATRA-resistant APL; however, a-TOS produced a moderate antagonistic effect on ATO-induced apoptosis when added simultaneously and an additive effect when added 24 h after ATO. 5 Here, we demonstrated that a-TOS is as effective as ATO or ATRA in a murine model of APL and that its interaction is not antagonistic in vivo. We emphasize that the model used in this study represents human APL pathogenesis 44 and that we demonstrated the action of a-TOS via two important outcomes: leukemic burden and survival. We could not demonstrate an advantage of the combination treatments that included a-TOS over the single drug treatments using our murine model. However, in the clinical setting, the combination of ATRA and ATO has been demonstrated to be very effective. 45 Therefore, the therapeutic potential of a-TOS needs to be carefully evaluated in the setting where ATRA and/or ATO are contraindicated. On the other hand, it would be interesting to analyze the interaction between ATRA/ ATO/a-TOS. In this setting, Miller et al. 46, 47 reported the potentiation of ATO-induced apoptosis in APL and other leukemia cells by 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (Trolox, a hydrophilic derivative of a-tocopherol in which the hydrophobic side chain is replaced by an ester group). However, differently from a-TOS, Trolox does not produce an anticancer effect per se. Interestingly, the dihydroquinone derivative adaphostin, which is chemically related to a-TOS and exhibits essentially the same biological properties, was shown to be toxic to leukemic cells but not to normal hematopoietic precursors. 27 In conclusion, we demonstrated an in vivo antileukemic action and a novel mitochondrial target for a-TOS, highlighting MRC complex I as a potential target for anticancer therapy.
